Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Understanding Experiences with Extended-Release Buprenorphine (XR-BUP) Among Provincially-Incarcerated Individuals with Opioid Use Disorder (OUD) in Ontario, Canada: A Longitudinal Pre- and Post-Release Qualitative Study

EF 2023-24

Résumé
Medications for opioid addiction are effective and result in decreases in drug use and overdoses, which is important for correctional populations as they face a heightened risk of overdose upon release from jail/prison. Attending a pharmacy daily to receive these medications makes it difficult to reintegrate into the community, and is a main reason why individuals discontinue treatment. A new opioid addiction medication, extended-release buprenorphine (XR-BUP; trade name Sublocade) is an injection individuals receive once a month which considerably reduces the number of required clinic visits, and may therefore be beneficial for correctional populations. However, limited Canadian information exists on incarcerated individuals' experiences and perceptions of Sublocade, particularly in comparison to traditional OAT medications such as Suboxone, including barriers, facilitators, and any health, social, and community reintegration impacts. The current project aims to interview 80 provincially-incarcerated individuals in Ontario receiving either Sublocade (40 individuals) or Suboxone (40 individuals), both during and post-incarceration, to examine these outcomes. Equal numbers of men and women will be recruited and interviews will be analyzed to identify and compare/contrast common themes and experiences, including any sex/gender differences. The research will be conducted in collaboration with the Ontario Ministry of the Solicitor General and will take approximately 3 years. The information from this project will have important clinical, public health, and policy implications as improved treatment can result in reduced risks for overdose, and enhanced social, health, and community reintegration outcomes. Results will be widely shared with stakeholders through webinars, conferences, and social networks, as well as published in academic journals and used to fulfill my PhD dissertation requirements.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
496604
Name
Russell Cayley
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Understanding Experiences with Extended-Release Buprenorphine (XR-BUP) Among Provincially-Incarcerated Individuals with Opioid Use Disorder (OUD) in Ontario, Canada: A Longitudinal Pre- and Post-Release Qualitative Study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Correctional Populations; Criminal Justice System; Drug Policy; Extended-Release Buprenorphine (Sublocade); Health Policy; Opioid Agonist Treatment (Oat); Opioid Use Disorder (Oud); Prison Research; Qualitative Research; Treatment
Abstract
Medications for opioid addiction are effective and result in decreases in drug use and overdoses, which is important for correctional populations as they face a heightened risk of overdose upon release from jail/prison. Attending a pharmacy daily to receive these medications makes it difficult to reintegrate into the community, and is a main reason why individuals discontinue treatment. A new opioid addiction medication, extended-release buprenorphine (XR-BUP; trade name Sublocade) is an injection individuals receive once a month which considerably reduces the number of required clinic visits, and may therefore be beneficial for correctional populations. However, limited Canadian information exists on incarcerated individuals' experiences and perceptions of Sublocade, particularly in comparison to traditional OAT medications such as Suboxone, including barriers, facilitators, and any health, social, and community reintegration impacts. The current project aims to interview 80 provincially-incarcerated individuals in Ontario receiving either Sublocade (40 individuals) or Suboxone (40 individuals), both during and post-incarceration, to examine these outcomes. Equal numbers of men and women will be recruited and interviews will be analyzed to identify and compare/contrast common themes and experiences, including any sex/gender differences. The research will be conducted in collaboration with the Ontario Ministry of the Solicitor General and will take approximately 3 years. The information from this project will have important clinical, public health, and policy implications as improved treatment can result in reduced risks for overdose, and enhanced social, health, and community reintegration outcomes. Results will be widely shared with stakeholders through webinars, conferences, and social networks, as well as published in academic journals and used to fulfill my PhD dissertation requirements.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Russell, Cayley
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~